In phase 2 trial, spesolimab cleared more lesions than placebo, but it was associated with infections, systemic drug reactions<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Dec. 27, 2021 (HealthDay News) — At one week, the incidence of lesion clearance was higher with spesolimab than placebo among patients with generalized pustular psoriasis (GPP), according to a study published in the Dec. 23 issue of the New England Journal of Medicine<\/em>.<\/p>\n Herv\u00c3\u00a9 Bachelez, M.D., Ph.D., from the Assistance Publique-H\u00c3\u00b4pitaux de Paris H\u00c3\u00b4pital Saint-Louis, and colleagues randomly assigned 53 patients with a GPP flare to receive a single dose of either spesolimab or placebo (35 and 18 patients, respectively). In both groups, patients could receive an open-label dose of spesolimab on day 8, an open-label dose of spesolimab as rescue medication after day 8, or both, and they were followed to 12 weeks. The primary end point was a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 to 4 (no visible pustules to severe pustulation) at week 1.<\/p>\n The researchers found that overall, 54 percent of patients in the spesolimab group and 6 percent in the placebo group had a pustulation subscore of 0 at week 1. Forty-three and 11 percent had a GPPGA total score of 0 or 1 in the spesolimab and placebo groups, respectively. Infections occurred in 17 percent of those assigned to spesolimab through the first week; at week 12, infections had occurred in 47 percent of those who received spesolimab at any time in the trial. Forty-six percent of those who received at least one dose of spesolimab had antidrug antibodies.<\/p>\n “Intravenous spesolimab resulted in higher rates of clearance of pustular lesions at one week than placebo but was associated with infections and systemic reactions,” the authors write.<\/p>\n Several authors disclosed financial ties to Boehringer Ingelheim, which manufactures spesolimab and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n